Most human studies of CBD have been done on people who have seizures, and the FDA recently approved the first CBD-based drug, Epidiolex, for rare forms of epilepsy. Clinical trials for other conditions are promising, but tiny. In one Brazilian study published in 2011 of people with generalized social anxiety disorder, for example, taking a 600-mg dose of CBD (higher than a typical dose from a tincture) lessened discomfort more than a placebo, but only a dozen people were given the pill.
Along with its better-known counterpart, THC (delta-9-tetrahydrocannabinol, the chemical that produces the marijuana high), CBD is one of more than 400 compounds found in the oils of cannabis plant species, which include marijuana and hemp. Unlike THC, CBD will not make you high. That said, this doesn’t mean CBD is not at all psychoactive, as many assert, says Jahan Marcu, Ph.D., director of experimental pharmacology and behavior at the International Research Center on Cannabis and Mental Health in New York City: “CBD does change cognition. It affects mood, which is why people take it for anxiety. And some find that it makes them more alert.”
The content that appears on this page is presented as an overview vs. comparative marketing. The provided information includes product information, overviews, buying guides, and product specifications. All trademarks, registered trademarks and service-marks mentioned on this site are the property of their respective owners. If something is factually inaccurate please contact us and let us know. By contributing your product facts helps to better serve our readers and the accuracy of the content.
Full spectrum (or “whole plant”) products contain CBD as well as terpenes and other cannabinoids such as CBG, CBN and trace amounts of THC. Usually these will be in ratios that were naturally-occurring and extracted from the plant and specific strain. Terpenes and cannabinoids are occasionally added back into products as an isolated form to raise the potency of the product.
Supercritical CO2 extraction is also the key to understanding more cannabinoids in cannabis like Cannabichromene (CBC) and cannabicitran (CBT) and how they interact with each other (called the Entourage effect). This can lead to increased understanding of marijuana in the medical field, and will also allow growers to come up with more effective, new and exciting strains.
CBD—or cannabidiol—is a type of cannabinoid, a family of molecules typically associated with marijuana, but in fact, also found in other plants and even humans (in us, they’re called endocannabinoids). There are hundreds of different cannabinoids in marijuana. The best known is tetrahydrocannabinol, or THC, a chemical in marijuana that targets and binds to certain receptors in the brain to give you a high. CBD is non-psychoactive and non-addictive, and it seems to bind to multiple target sites, thereby affecting a range of systems throughout the body.
Isolate CBD is the CBD gets its extraction from the cannabis plant without other terpenes and cannabinoids. Many users of this CBD type consider this much better than the full spectrum. They go as far enough to get this type of CBD by isolating the CBD from others themselves. They are even different dosage methods and levels for each kind of CBDs and therefore should carefully be in separation for each of the CBD types.
CBD hemp oil has a number of uses and comes in many forms including capsules, tinctures, sublingual supplements, liquid oil, oil as a paste, sprays, salves, creams and in edible forms, such as candies or sweets. You can also inhale CBD oil from vapor-releasing pens, similar to the technology for e-cigarettes. This variety also provides a lot of controlled flexibility in terms of concentration, making CBD hemp oil useful and desirable for people of all ages, economic means, and personal needs.
Zuardi, A. W., Crippa, J. A., Hallak, J. E., Bhattacharyya, S., Atakan, Z., Martin-Santos, R., … & Guimarães, F. S. (2012). A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation [Abstract]. Current Pharmaceutical Design, 18(32), 5,131–5,140. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/22716160